Cambridge Healthtech Institute’s 2nd Annual

PROTACs and Targeted Protein Degradation

Part 1: Emerging Protein Degradation Pathways

September 16-17, 2020

Part 2: Novel Protein Degraders

September 17-18, 2020

 

The ubiquitin-proteasome system (UPS) and the autophagy-lysosome system are the two major pathways responsible for protein degradation and maintenance of proteostasis. They consist of well-controlled, selective mechanisms for intracellular protein degradation and turnover. However, the diversity and complexity of the processes involved make it difficult to target these pathways for therapeutic intervention. The development of high-quality chemical probes, small molecule modulators, assays and screening platforms have helped identify various UPS and autophagy targets, as well as novel chemical and biological degrades for discovery and therapeutic applications. Cambridge Healthtech Institute’s conference on PROTACs and Targeted Protein Degradation will bring together chemists, biologists and pharmacologists to discuss the promise and challenges that lie ahead.

 

Who should attend: Scientists in Molecular and Cellular Biology, Discovery Biology, Target Discovery, Medicinal Chemistry, Discovery Chemistry, Lead Discovery, DMPK, Pharmacology, Target Identification and Validation, Chemical Biology, Proteomics, Assay Development, and Molecular Screening.

 

Part 1:

The UPS and autophagy pathways hold a lot of promise in seeking out previously “undruggable” targets and for therapeutic intervention. The first part of the PROTACs and Targeted Protein Degradation conference will focus on identifying different ligases, chaperone proteins, deubiquitinating enzymes (DUBs) and proteins that can be modulated for hijacking the ubiquitin-proteasome and autophagy driven protein degradation. 

 

Coverage will include, but is not limited to:

  • Emerging tools and assays to simulate, probe and quantify the autophagy/ubiquitin pathways
  • Identifying ligases, DUBs and chaperones proteins for hijacking the UPS
  • Role of UPS/autophagy in oncology, CNS, autoimmune, metabolic and infectious diseases
  • Understanding the differences and crosstalk between the UPS and autophagy pathways
  • Exploiting the interplay between autophagy, ubiquitin and immune responses
  • Choosing and pursuing degradable protein targets: KRAS, transcription factors and more

 

Part 2:

The UPS and autophagy pathways act as key regulators in cancer, CNS and other diseases. Small molecules such as proteolysis-targeting chimeras (PROTACs), E3 ligase modulators like thalidomides, DUB inhibitors, as well as other chemical and biological entities are being developed to hijack the UPS and trigger targeted protein degradation. However, some challenges do exist in terms of stability, biodistribution and penetration of these molecules in vivo. The second part of the PROTACs and Targeted Protein Degradation conference will discuss ways to design and optimize these molecules for better in vitro to in vivo translation.      

 

Coverage will include, but is not limited to:

  • Designing and optimizing PROTACs for tackling undruggable targets
  • Chemically diverse small molecules (IMiDs, CIDEs, SNIPERs and more) for targeted protein degradation
  • Emerging assays and cellular screening platforms for finding efficient degraders
  • New probes and modulators of chaperones, DUBs, E2 and E3 ligases for targeting the UPS
  • Development of macrocyclic and peptide-based PROTACs
  • Use of new linkers and binders like nanobodies, antibodies and more
  • Optimizing pharmacokinetic properties: specificity, stability, penetration and biodistribution     

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is February 26, 2020.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute

Email: tkoppal@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com